| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 26,910 | 27,340 | 02.09. | |
| 27,040 | 27,300 | 02.09. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01:46 | Biogen Inc.: Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status | LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive... ► Artikel lesen | |
| Di | Alzheimer's Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug | ||
| Mo | Eisai's Leqembi unlocks at-home dosing with FDA autoinjector approval | ||
| Mo | FDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's | ||
| Mo | Eisai: FDA Approves LEQEMBI IQLIK For Maintenance Dosing In Treatment Of Early Alzheimer's | WESTON (dpa-AFX) - Eisai and Biogen (BIIB) announced that the FDA has approved the Biologics License Application for once weekly lecanemab-irmb subcutaneous injection, or LEQEMBI IQLIK, for... ► Artikel lesen |
